ALLG at ASH 2025 – Global Leaders, Global Impact
The 67th American Society of Hematology (ASH) Annual Meeting and Exposition 2025 represents an important moment for the Australasian Leukaemia & Lymphoma Group (ALLG) with 10 ALLG trial abstracts accepted, including two oral presentations and eight poster presentations. Our ALLG member researchers are once again demonstrating the global impact of our Australian-led blood cancer clinical trial research.
ALLG’s presence at ASH is underscored by our mission – driving innovative clinical trial research that translates into Better treatments…Better lives for people with blood cancers.
About the American Society of Hematology (ASH)
The American Society of Hematology (ASH) is the world’s largest professional haematology society, with a global membership of more than 18,000 haematologists from approximately 100 countries who work together with one aim – to conquer blood disease. ASH 2025, the world’s largest blood conference, supports haematologists in fostering high-quality, equitable care, transformative research, and innovative education to improve the lives of patients with blood and bone marrow disorders.
ALLG Members Leading the Charge
Our members have a strong presence at the upcoming ASH 2025 Annual Meeting and Exposition, cementing ALLG as a true Global Leader in haematology research, including two prestigious podium presentations and eight poster presentations. Research abstracts accepted for presentation at ASH represent the most important, novel research in the field and are selected through an extensive peer review process.
We congratulate all members for being selected to present at ASH 2025. The ALLG trial results to be presented are:
Oral Presentations
MM25 Viber-M
Dr Shirlene Sim
Interim analysis of efficacy and safety for ALLG MM25 (Viber-M): A phase I b/II study of venetoclax, iberdomide and dexamethasone for patients in first or second relapse of multiple myeloma with t(11;14).
The findings of the interim analysis have recently been published in Blood Cancers Today.
NHL35 PACIFIC
Dr Katharine Lewis
Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial.
Reflecting on the abstract’s acceptance to ASH Dr Lewis said, “I am excited to present the interim results from the PACIFIC NHL35 study, a phase II study investigating chemoimmunotherapy in combination with pembrolizumab, for first-line therapy for a rare lymphoma subtype; primary mediastinal B-cell lymphoma (PMBL). At this interim stage, it is particularly exciting to see the low rates of lymphoma progression after this treatment, and the high rates of undetectable cancer in the blood (know as circulating tumour DNA) with almost half of patients having undetectable levels after two cycles of immunotherapy, even before they initiate their chemotherapy. This observation raises the possibility to explore in future research whether therapy for PMBL may be able to be successfully de-escalated for some patients, reducing unwanted treatment effects without compromising their chance of cure.”
Poster Presentations
ALLG HSANZ Fellow
Dr Arina Martynchyk
Patient reported outcome design, conduct and reporting in Australasian Leukaemia & Lymphoma Group (ALLG) cooperative group trials. 2025 Fellowship research project.
Reflecting on the abstract’s acceptance to ASH Dr Martynchyk said, “The ALLG HSANZ Fellow project’s results being presented at ASH highlights the critical role of patient-reported outcomes in shaping modern haematology trials. By revealing both the progress and remaining gaps in PRO design and reporting across 18 years of ALLG studies, this work provides an evidence base that can meaningfully strengthen future trial quality and patient-centred research.”
AMLM31 / HO181 Blex
Prof Andrew Wei
Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25 / ALLG AMLM31.
ALL08 BLAM
Prof David Ritchie
Immunological responses to blinatumomab treatment in B-acute lymphoblastic leukaemia (B-ALL) patients – Australasian Leukaemia and Lymphoma Group ALL08 BLAM study.
MM23 SeaLAND
Dr Matthew Rees
Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma.
Reflecting on the abstract’s acceptance to ASH Dr Rees said, “The SeaLAND trial demonstrates that adding selinexor to lenalidomide maintenance after transplant did not improve outcomes and significantly increased toxicity, with grade ≥3 adverse events nearly doubling and treatment doses reduced across both drugs. These findings suggest selinexor is poorly suited to the maintenance setting, a low disease burden state where the selection of a tolerable therapy is important. While the study was underpowered due to early termination, any potential benefit may be confined to patients with high-risk cytogenetics.”
AMLM22 D4 CADENCE
Dr Victoria Ling
Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia.
Reflecting on the abstract’s acceptance to ASH Dr Ling said, “The CADENCE trial is an innovative trial harnessing a novel immunotherapeutic in AML maintenance. It’s acceptance as a ‘Trial in progress’ indicates its exciting potential to improve standard of care to prevent relapse in this disease.”
AMLM27 IMpress
Prof Stephen Lane
A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study.
MM22 FRAIL-M
Dr Sueh-Li Lim
Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study.
NHL27 RELEVANCE
Prof Judith Trotman
Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: a post-hoc analysis of the RELEVANCE trial.
What this Means for Patients
Presenting at ASH has real-world implications for patients across Australia and New Zealand. By sharing our research findings and data on the world stage, ALLG helps bring new therapies closer to home. Through our continued collaborations with our international partners, and through presentation of our clinical trial results, we are accelerating potential life-changing treatments into new global standards of cancer treatment and care.
ALLG Chief Executive Officer, Delaine Smith, said, “The ALLG is the only collaborative blood cancer clinical trial group in Australasia, conducting clinical trials into MDS, AML and other leukaemias, lymphomas and myeloma. Our independent, clinician-led network enables us to conduct research into all areas of blood cancers, including rarer cancers and areas of high unmet need. We’re excited to launch the MESSAGE clinical trial to improve the outcomes and quality of life for transfusion-dependant MDS patients and delighted to work with Syntara whose original research underpins this new treatment concept.”
ALLG SAC Chair, Prof Judith Trotman, said, “As ALLG Scientific Advisory Committee Chair, I am thrilled the ALLG NHL35 PACFIC trial has been accepted as an Oral Presentation at ASH 2025. The results from the interim analysis are incredibly encouraging and highlights the strong potential of this trial to improve outcomes for patients with primary mediastinal B-Cell lymphoma and impact global standard of care. Congratulations to Professor Chan Cheah & Dr Katharine Lewis.”
About ALLG’s Blood Cancer Research
ALLG is the only collaborative, not-for-profit blood cancer clinical trial group in Australasia. Our mission is to create Better treatments…Better lives for patients with blood cancer.
ALLG’s 1,400 + researcher members design and conduct clinical trials across all blood cancers, including Acute and Chronic Leukaemia’s, Non-Hodgkin and Hodgkin Lymphomas, Multiple Myeloma, Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPNs).
ALLG’s clinical trials and research have driven progress in blood cancer treatments and have improved survival rates for patients for over 50 years. As we look to 2026 and beyond, ALLG is driving forward a strong collaborative clinical research program across all blood cancers to accelerate science, generate high-quality evidence and deliver effective treatments and outcomes for patients.
You can help support our research, as we aim for a world where all blood cancers can be treated effectively, and even cured.
Memberships
Donations
Clinical Trials & Research